2026近期合作 & 交易事件01 睿跃生物被Gyre收购02 黑石押注梯瓦开发TL1A单抗03 正大天晴新药授权赛诺菲04 德琪医药CD3/CD19双抗授权给优时比05 施维雅25亿美元收购Day One01睿跃生物被Gyre收购2026年3月2日,美国Gyre Therapeutics宣布将以全股票交易方式收购睿跃生物(Cullgen),交易估值约3亿美元。根据协议条款,Cullgen将成为...
Source Link2026近期合作 & 交易事件01 睿跃生物被Gyre收购02 黑石押注梯瓦开发TL1A单抗03 正大天晴新药授权赛诺菲04 德琪医药CD3/CD19双抗授权给优时比05 施维雅25亿美元收购Day One01睿跃生物被Gyre收购2026年3月2日,美国Gyre Therapeutics宣布将以全股票交易方式收购睿跃生物(Cullgen),交易估值约3亿美元。根据协议条款,Cullgen将成为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.